International, Multicenter, Single-Arm, Open-Label, 12-Week Phase IIIb Study to Evaluate RebiSmart Suitability for Self Injection of Rebif New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS) [Estudio de fase IIIb, de un solo brazo, abierto, 12 semanas de duracion, multicentrico e internacional, dirigido a evaluar la adecuacion de RebiSmartTM para la autoinyeccion de Rebif® Nueva Formulacion (RNF) en cartucho multidosis en pacientes con esclerosis multiple recidivante (EMR)].

Trial Profile

International, Multicenter, Single-Arm, Open-Label, 12-Week Phase IIIb Study to Evaluate RebiSmart Suitability for Self Injection of Rebif New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS) [Estudio de fase IIIb, de un solo brazo, abierto, 12 semanas de duracion, multicentrico e internacional, dirigido a evaluar la adecuacion de RebiSmartTM para la autoinyeccion de Rebif® Nueva Formulacion (RNF) en cartucho multidosis en pacientes con esclerosis multiple recidivante (EMR)].

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2012

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BRIDGE
  • Sponsors EMD Serono
  • Most Recent Events

    • 12 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 14 Sep 2009 Results were presented at ECTRIMS 2009, according to a Merck Serono media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top